Shotaro Fujita
Fukushima Medical University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Shotaro Fujita.
PLOS ONE | 2018
Masaru Noda; Hirokazu Okayama; Yasuhide Kofunato; Shun Chida; Katsuharu Saito; Takeshi Tada; Mai Ashizawa; Takahiro Nakajima; Keita Aoto; Tomohiro Kikuchi; Wataru Sakamoto; Hisahito Endo; Shotaro Fujita; Motonobu Saito; Tomoyuki Momma; Shinji Ohki; Koji Kono
The expression of fucosyltransferase 8, an enzyme responsible for core fucosylation encoded by FUT8, influences tumor biology and correlates with patient prognosis in several solid cancers. We hypothesized that p53 alteration modifies prognostic associations of FUT8 expression in colorectal cancer (CRC), since FUT8 has recently been identified as a direct transcriptional target of wild-type p53. Utilizing multiple datasets of microarray and RNA sequence of CRC, FUT8 mRNA was found to be highly expressed in wild-type p53 tumors (n = 382) compared to those of mutant p53 (n = 437). Prognostic values of FUT8 expression in conjunction with the p53 status for disease-free survival (DFS) were analyzed using two independent cohorts of stage II and III CRC after curative surgery, including the immunohistochemistry (IHC) cohort (n = 123) and the microarray cohort (n = 357). In both cohorts, neither FUT8 expression nor the p53 status was associated with DFS. Strikingly, positive expression of FUT8 protein was significantly associated with better DFS only in tumors with negative p53, while it had no prognostic impact in tumors with positive p53 in the IHC cohort. Although not statistically significant, a similar prognostic trend was observed in the microarray cohort when patients were stratified by the p53 status. Our results suggest that the prognostic values of FUT8 expression on DFS may be modified by the p53 status, and the expression of FUT8 protein can be a prognostic biomarker for patients with stage II and III CRC.
Fukushima journal of medical science | 2018
Tatsuo Shimura; Masahiko Shibata; Kenji Gonda; Suguru Hayase; Wataru Sakamoto; Hirokazu Okayama; Shotaro Fujita; Motonobu Saito; Tomoyuki Momma; Shinji Ohki; Koji Kono
AIMS We aimed to investigate the relationship of colorectal cancer prognosis and inflammatory parameters, including neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR), with reference to circulating myeloid-derived suppressor cells (MDSCs) in the current study. PATIENTS AND METHODS Thirty-five patients who underwent curative-intent surgery were enrolled. A receiver-operating characteristic curve (ROC) was used to assess the usefulness of candidates for prognostic factors. Recurrence-free survival (RFS) was calculated using the Kaplan-Meier method, and the candidates for prognostic factors were assessed by a Cox proportional hazard model. RESULTS ROC curve analyses determined cutoff values for NLR and LMR as 2.9 and 2.4, respectively. The percentage of MDSCs in patients with LMR ≤ 2.4 was statistically higher than in those with LMR > 2.4 (p = 0.012). The patients with LMR ≤ 2.4 exhibited a statistically lower RFS than those with LMR > 2.4 (p = 0.008). These results were also observed in patients with stage II + III disease. LMR was an independent prognostic factor of RFS in colorectal cancer patients (hazard ratio: 7.757, 95% confidence interval: 1.462-41.152, p = 0.016). CONCLUSION Lower LMR was associated with poor prognosis in colorectal cancer patients; whereas, higher circulating MDSCs were observed in patients with lower LMR.
Annals of Cancer Research and Therapy | 2010
Shotaro Fujita; Yoshihisa Koyama; Masashi Higashimoto; Koichiro Ono; Tomojiro Ono; Kumiko Watanabe; Nobuhiro Yoshimoto; Tomoyuki Momma; Masaru Saito; Hidekazu Sugeno; Motoki Sassa; Teruhide Ishigame; Wataru Sakamoto; Noriko Abe; Takashi Yazawa; Kotaro Miyamoto; Kazunoshin Tachibana; Manabu Iwadate; Toru Ohtake; Yuji Takebayashi; Seiichi Takenoshita
Annals of Cancer Research and Therapy | 2010
Yoshihisa Koyama; Masashi Higashimoto; Kenji Gonda; Jun Ito; Nobuhiro Yoshimoto; Tomoyuki Momma; Masaru Saito; Maiko Ishii; Hirokazu Okayama; Yoshiko Matsumoto; Hidekazu Sugeno; Motoki Sassa; Teruhide Ishigame; Shotaro Fujita; Wataru Sakamoto; Noriko Abe; Manabu Iwadate; Takashi Ohshima; Kojiro Urazumi; Koichi Nakayama; Yuji Takebayashi; Seiichi Takenoshita
Gan to kagaku ryoho. Cancer & chemotherapy | 2006
Sekikawa K; Onogi H; Yazawa T; Yu Sato; Sakamoto W; Miyamoto K; Shotaro Fujita; Shinichi Suzuki; Yoshiyuki Endo; Shinji Ohki; Seiichi Takenoshita
Nihon Rinsho Geka Gakkai Zasshi (journal of Japan Surgical Association) | 2004
Shotaro Fujita; Kensuke Kumamoto; Wataru Igarashi; Koju Sugano; Masami Hoshino; Seiichi Takenoshita
Gastroenterology | 2018
Leo Yamada; Wataru Sakamoto; Daisuke Ujiie; Tomohiro Kikuchi; Mai Ashizawa; Hirokazu Okayama; Katsuharu Saito; Hisahito Endo; Shotaro Fujita; Motonobu Saito; Misato Sakuyama; Hiroshi Nakano; Kenji Gonda; Azuma Nirei; Takeshi Tada; Suguru Hayase; Hiroyuki Hanayama; Kousaku Mimura; Zenichiro Saze; Tomoyuki Momma; Masahiko Shibata; Shinji Ohki; Koji Kono
Drug Resistance and Modifiers | 2018
Motonobu Saito; Hisashi Onozawa; Misato Sakuyama; Mai Ashizawa; Tomohiro Kikuchi; Hirokazu Okayama; Hisahito Endo; Shotaro Fujita; Wataru Sakamoto; Zenichiro Saze; Tomoyuki Momma; Shinji Ohki; Koji Kono
Annals of Cancer Research and Therapy | 2018
Motonobu Saito; Katsuharu Saito; Hiroshi Nakano; Tomohiro Kikuchi; Hirokazu Okayama; Shotaro Fujita; Hisahito Endo; Wataru Sakamoto; Tomoyuki Momma; Shinji Ohki; Koji Kono
Gan to kagaku ryoho. Cancer & chemotherapy | 2015
Shotaro Fujita; Tomoyuki Monma; Shinji Ohki; Murakami Y; Hirokazu Okayama; Yazawa T; Takawa M; Kensuke Kumamoto; Tohru Ohtake; Koji Kono; Seiichi Takenoshita